TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06755346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis plant (THC 40mg)
Description: Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
Study: NCT06757010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE3107
Description: NE3107 20 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT06758193

Intervention type: OTHER
Intervention: No intervention was applied in this study.
Description: No intervention was applied in this study.
Study: NCT06756477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness group
Description: Online training will be implemented 2 times a week for 8 sessions. A 30-45 minute reminder training will be given 1 month after the training. Mindfulness-Based Healthy Living Behaviors Education (MTSYDE) booklet will be sent online to guide students' home practices. Taking into account the possibility of forgetting and demotivation in students, audio recordings will be used, reminder messages will be sent and counseling will be given regarding the program. A post-test will be administered 1 month after the reminder training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: Menstruation-specific Healthy Living Behaviors training of 30-45 minutes in 8 sessions 2 times a week will be provided online. A standard training booklet will be sent 1 month after the training as a reminder. Standard reminder messages will be sent considering the possibility of forgetting and demotivation in students. A post-test will be administered 1 month after the reminder training.
Study: NCT06755749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Planning Education
Description: Stage 1 (Day 1, 10-15 min): The education content for Session 1 in the FP Education Booklet prepared by the researchers was provided to the participants using the face-to-face interview method. After making an appointment for Stage 2 (Day 3) to be carried out at the FHC, the first stage of the data collection process was complete.~Stage 2 (Day 3, 10-15 min): The education content for Session 2 in the FP Education Booklet was provided to the participants who arrived at the FHC on their predetermined appointment days using the face-to-face interview method. After making an appointment for Stage 3 (Day 7) to be carried out at the FHC, the second stage of the data collection process was complete.~Stage 3 (Day 7, 1-5 min): The data collection forms were administered again to the participants who arrived at the FHC on their appointment days assigned at Stage 2, and the data collection process was complete.
Study: NCT06030037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Responder-Derived Fecal microbiota transplantation (R-FMT
Description: R-FMT (induction) via colonoscopy on C1D1 and C3D1. R-FMT (maintenance) via sigmoidoscopy will be repeated every 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered at 20 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib will be administered at 20 mg daily
Study: NCT05829668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABA-based functional analysis and treatment
Description: Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
Study: NCT05764395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib
Description: Given by mouth

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05827601

Intervention type: DIAGNOSTIC_TEST
Intervention: respiratory specimen
Description: participants will perform self-sampling with a nasopharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: respiratory specimen
Description: participants will perform self-sampling with a nasopharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: respiratory specimen
Description: participants will perform self-sampling with a nasopharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: respiratory specimen
Description: participants will perform self-sampling with a nasopharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: serum
Description: participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
Study: NCT05435846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given orally
Study: NCT05083897

Intervention type: OTHER
Intervention: hip adduction isometric contraction
Description: addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
Study: NCT05297773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group
Description: The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to a maximum of 64% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Group
Description: Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will perform a weekly stretching/relaxation session for 45 minutes.
Study: NCT05021432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality training group
Description: This group will receive video based games

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit Training group
Description: They will receive Task-oriented Circuit training exercise program
Study: NCT04698226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
Study: NCT05764395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study: NCT04698226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole.
Study: NCT05122559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
Study: NCT05363540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre-incisional parasternal intercostal block
Description: LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post-incisional parasternal intercostal block
Description: LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
Study: NCT05901103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block (SPSIPB)
Description: Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
Study: NCT05929339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous oxytocin
Study: NCT06507670

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound
Description: Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound
Description: Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings
Study: NCT06507384

Intervention type: OTHER
Intervention: AI-Based Risk Assessment Model
Description: Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
Study: NCT05771961

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: coronary pressure/temperature sensor-tipped guidewire
Description: In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: coronary pressure/temperature sensor-tipped guidewire
Description: In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-derived index of microcirculatory resistance (IMRangio)
Description: Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-derived index of microcirculatory resistance (IMRangio)
Description: Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
Study: NCT05715515

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panbio™
Description: The Panbio™ COVID-19/Flu A\&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users
Study: NCT06295705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hip-Hop Dance
Description: I. Week 1 - Session 1~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Hip-Hop~4. Cool-Down: Deep Breathing~5. Debrief Check-In~II. Week 2 - Session 2~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Locking~4. Cool-Down: Instructed Yoga~5. Debrief Check-In~III. Week 3 - Session 3~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Breaking~4. Cool-Down: Sensory Time~5. Debrief Check-In~IV. Week 4 - Session 4~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Popping~4. Cool-Down: Animal Deep Breathing~5. Debrief Check-In~V. Week 5 - Session 5~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Learn Showcase Routine~4. Cool-Down: Animal Instructed Yoga~5. Debrief Check-In~VI. Week 6 - Session 6~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Review Showcase Routine~4. Cool-Down: Sensory Time~5. Debrief Check-In~VII. Week 7 - Dance Showcase
Study: NCT04881747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasmiditan
Description: Administered orally.
Study: NCT05077592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Povidone Iodine
Description: Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
Study: NCT05028257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines
Description: Pursuit of vaccination in case of anaphylactic reaction
Study: NCT04924166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dose of capsules that appear identical to active dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 180 mg in capsule form
Study: NCT06128915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaccine
Description: Vaccination against 20 serotypes of S. pneumoniae
Study: NCT06237621

Intervention type: DEVICE
Intervention: SnapshotNIR imaging
Description: SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
Study: NCT05862740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Debulking Surgery in advanced ovarian cancer
Description: Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparotomic Debulking Surgery in advanced ovarian cancer
Description: Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
Study: NCT05910242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham-RIC is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
Study: NCT04718376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
Description: All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study: NCT04902573

Intervention type: OTHER
Intervention: Non-interventional
Description: As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
Study: NCT05623111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinumtoxin-A 100 UNIT Injection
Description: Perineural injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
Study: NCT04878536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen drink
Description: Testing product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blank
Description: Placebo drink
Study: NCT05735756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram 20mg
Description: Citalopram 20mg once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 12 weeks
Study: NCT05764915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-264 phosphate tablets
Description: RGT-264 phosphate tablets will be administered orally once daily (QD).
Study: NCT05074212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Factorial Assignment
Description: At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Factorial Assignment
Description: At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
Study: NCT06448819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patients received Crohn's disease exclusion diet or Mediterranean diet
Study: NCT05085912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
Study: NCT06116695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human treated dentin matrix
Description: human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mineral Tri-Oxide Aggregate
Description: mineral trioxide aggregate was used as control
Study: NCT06421779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)
Description: Children watch underwater experience video by wearing the virtual reality glass during the skin prick test.
Study: NCT04843696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)
Description: the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12\~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.